Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 445 across all filing types
Latest filing 2025-04-30 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物关于股东权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement regarding a change in shareholding by a significant shareholder (ABA-Bio) of the company 益方生物科技（上海）股份有限公司. It details the reduction in shareholding percentage from 5.73% to 5.00%, the nature of the shares, and confirms that this change does not affect control of the company. The document references compliance with securities laws and disclosure requirements related to shareholding changes. There is no financial data, earnings information, or management discussion present. The content fits the definition of a Major Shareholding Notification, which reports changes in significant share ownership levels crossing thresholds (in this case, the 5% threshold). The document length is short and focused solely on shareholding changes, not a full report or announcement of a report publication. Therefore, the correct classification is Major Shareholding Notification (MRQ).
2025-04-30 Chinese
益方生物2025年第一季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as the "2025 First Quarter Report" of 益方生物科技（上海）股份有限公司, indicating it is a quarterly financial report. It contains detailed financial statements including balance sheet, profit and loss statement, and cash flow statement for the first quarter of 2025. The report explicitly states it is unaudited and includes comprehensive financial data and analysis for the quarter. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is over 12,000 characters, so it is not a mere announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2025
2025-04-28 Chinese
益方生物2024年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024年度募集资金存放与实际使用情况的专项报告" which translates to "2024 Annual Report on the Deposit and Actual Use of Raised Funds." It details the amount of funds raised, their deposit, usage, management, and changes in investment projects related to the raised funds. It references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange, and includes detailed financial figures and tables about the use of raised capital. The document is a comprehensive report on the management and use of capital raised through the company's initial public offering (IPO). This type of report is specific to capital raising and usage updates, which aligns with the category "Capital/Financing Update (CAP)" as it provides detailed information on fundraising and capital usage rather than a general annual report or earnings release. The document length (9190 characters) and detailed financial data confirm it is a substantive report, not just an announcement or certification. Therefore, the most appropriate classification is CAP.
2025-04-25 Chinese
益方生物内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and responsibilities of the company and the auditors regarding internal control over financial reporting as of December 31, 2024. The document includes an audit opinion on the effectiveness of internal controls related to financial reporting. It is issued by a certified public accountant firm and signed by auditors. The content is focused on the audit of internal controls rather than the full annual report or financial statements. The document length is 2815 characters, which is relatively short but contains substantive audit content, not just an announcement or certification. Therefore, it fits the category of an Audit Report / Information (AR) rather than an Annual Report (10-K) or Regulatory Filing (RNS). FY 2024
2025-04-25 Chinese
益方生物2024年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (立信会计师事务所) for the 2024 fiscal year audit of 益方生物科技（上海）股份有限公司. It details the qualifications, risk capacity, audit records, audit work plan, quality management, and information security management related to the audit firm. The content focuses on the audit firm's performance and compliance with regulations during the 2024 audit process. It does not contain actual financial statements or substantive financial data of the company itself, nor is it a full audit report or annual report. Instead, it is an assessment or evaluation report about the audit firm's duties and performance. This fits the definition of an Audit Report / Information (AR) which includes standalone audit reports and applied accounting principles or evaluations related to audits, excluding full annual reports. The document length is 3642 characters, which is sufficient to be a report rather than a brief announcement. Therefore, the classification is AR with high confidence. FY 2024
2025-04-25 Chinese
益方生物独立董事年度述职报告（严嘉）
Board/Management Information Classification · 95% confidence The document is an Independent Director's Annual Work Report for the year 2024 from a company named 益方生物科技（上海）股份有限公司. It details the independent director's activities, attendance at board and committee meetings, communication with auditors, review of financial reports, and other governance-related duties. The content focuses on the director's role, oversight, and governance activities rather than presenting financial statements or audit results themselves. This type of document is a report on board/management information, specifically about the independent director's duties and performance over the year. It is not an annual report, audit report, or regulatory filing. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 4114 characters, which is consistent with a detailed report but not a full financial report.
2025-04-25 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.